Geron Corp
Open
SectorHealthcare
1.29 -3.73
Overview
Share price change
24h
Min
1.3
Max
1.3599999999999999
Income | 25M -3.6M |
|---|---|
Sales | 3.8M 52M |
EPS | -0.005 |
Profit margin | -7.026 |
Employees | 258 |
EBITDA | 27M 3.8M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +217.46% upside |
Next Earnings | 5 Aug 2026 |
|---|
Market Cap | -268M 738M |
|---|---|
Previous open | 5.02 |
Previous close | 1.29 |
News Sentiment
By Acuity
4%
96%
3 / 342 Healthcare
Geron Corp Chart
Past performance is not a reliable indicator of future results.
About Geron Corp
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
